Verrica Pharmaceuticals Inc. (1NE.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:01AM CEST. Market open.
| Previous close | 8.72 |
| Open | 8.62 |
| Bid | 8.64 x 0 |
| Ask | 8.77 x 0 |
| Day's range | 8.62 - 8.62 |
| 52-week range | 2.60 - 8.72 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 368.927M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.64 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.83 |
GlobeNewswireVerrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a minimal impact on Verrica’s cash position Common warts is one of the largest and most underserved patient populations in medical dermatology with a prevalence of ~22M in the U.S. and no FDA approved products; Verrica believes com
- GuruFocus.com
Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Explore Verrica Pharmaceuticals' financial performance, strategic partnerships, and operational insights from the first quarter of 2024.
GuruFocus.comVerrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review
Exploring Verrica's Financial Outcomes and Strategic Developments in the First Quarter
© 2024 Yahoo. All rights reserved.